Jazz Pharmaceuticals, Inc. Stock Prediction
AI-powered sentiment analysis and prediction trends for JAZZ, updated each market day.
JAZZ AI Sentiment
AI sees no strong directional signal for Jazz Pharmaceuticals, Inc. stock over the next 10 market days.
Prediction date: April 10, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About Jazz Pharmaceuticals, Inc.
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
Sector
Exchange
Market Cap
$12,197,567,749
Cap Tier
Employees
2,890
Headquarters
DUBLIN
Listed Since
June 1, 2007
JAZZ Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
JAZZ Volatility
Jazz Pharmaceuticals, Inc. has shown moderate price volatility over the last 5 trading days. Moderate volatility indicates normal market activity with typical price fluctuations.
